

P&T Motion History Insomnia Drugs (Sedative Hypnotics)

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<u>Benzodiazepine Receptor Agonists</u> eszopiclone zaleplon zolpidem <u>Non-Benzodiazepine Receptor Agonists</u> doxepin ramelteon <u>Dual Orexin Receptor Antagonists</u> daridorexant lemborexant suvorexant	Dual Orexin Receptor Antagonists (DORAs) for Insomnia The newer sedative hypnotics will be considered as three subclasses, benzodiazepine receptor agonists (eszopiclone, zaleplon, zolpidem and long acting zolpidem), non-benzodiazepine receptor agonists (doxepin and ramelteon), and orexin antagonists (daridorexant, lemborexant and suvorexant). After considering the evidence of safety, efficacy and special populations for the treatment of Dual Orexin Receptor Antagonists (DORAs) for Insomnia, I move that daridorexant, lemborexant and suvorexant are safe and efficacious for the treatment of their approved indications. The Dual Orexin Receptor Antagonists (DORAs) for Insomnia can be subject to therapeutic interchange in the Washington preferred drug list. Based on prior consideration of safety, efficacy and special populations for the treatment of insomnia, I move that the benzodiazepine receptor agonists (eszopiclone, zaleplon, zolpidem and long-acting zolpidem) and non-benzodiazepine receptor agonists (doxepin and ramelteon) are safe and efficacious. The benzodiazepine receptor agonists can be subject to therapeutic interchange within their subclass in the	October 15, 2025	N/A	No	Passed unanimous

Bold = New from this report

Grey = not reviewed

Grey* = not part of the PDL

10/23/2025

P&T Motion History
Insomnia Drugs (Sedative Hypnotics)

	Washington preferred drug list for the treatment of insomnia. At least one drug from each of the three sub-classes must be preferred. Motion: Park 2nd: Hudson				
--	--	--	--	--	--

Bold = New from this report

Grey = not reviewed

Grey* = not part of the PDL

10/23/2025